NATALIA BACHURINA: Open Payments
NPI 1144502956 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,600 in 58 payments from 15 companies in 2025. Trend: 2023 $1,517 · 2024 $1,518 · 2025 $1,600
Food & beverage: $1,513Education: $87
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 17 | $477 |
| Otsuka America Pharmaceutical, Inc. | 9 | $221 |
| Ardelyx, Inc. | 3 | $181 |
| AstraZeneca Pharmaceuticals LP | 4 | $170 |
| Amgen Inc. | 4 | $90 |
| OPKO Pharmaceuticals, LLC | 4 | $87 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| Optinose US, Inc. | 3 | $69 |
| SHIELD THERAPEUTICS INC | 3 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
Products named: NUCALA, JYNARQUE, FARXIGA, XPHOZAH 30 MG, RAYALDEE, Xhance, ACCRUFER, Fabhalta.
Industry payments across NY — which companies pay providers there.
